Showing 1 to 12 of 18 results
FDA Reviews Mifepristone Safety Amidst Political Pressure
The FDA is reviewing mifepristone's safety and efficacy following pressure from Republican attorneys general and concerns about its expanded telehealth access, despite decades of evidence supporting its safety.
FDA Reviews Mifepristone Safety Amidst Political Pressure
The FDA is reviewing mifepristone's safety and efficacy following pressure from Republican attorneys general and concerns about its expanded telehealth access, despite decades of evidence supporting its safety.
Progress
28% Bias Score
Kennedy Claims Biden Admin "Twisted Data" on Abortion Pills, Threatens Rollback
US Health Secretary Robert F Kennedy Jr. accused the Biden administration of manipulating data on abortion pills, suggesting potential rollbacks of expanded access regulations, a claim disputed by over 100 studies confirming the pills' safety and efficacy.
Kennedy Claims Biden Admin "Twisted Data" on Abortion Pills, Threatens Rollback
US Health Secretary Robert F Kennedy Jr. accused the Biden administration of manipulating data on abortion pills, suggesting potential rollbacks of expanded access regulations, a claim disputed by over 100 studies confirming the pills' safety and efficacy.
Progress
28% Bias Score
Mifepristone Shows Promise in Breast Cancer Prevention Despite Barriers
Research suggests mifepristone, a drug used in medical abortions, may prevent breast cancer by blocking progesterone's effects on breast cells; however, ethical concerns, high costs, and limited large-scale trials hinder its wider application.
Mifepristone Shows Promise in Breast Cancer Prevention Despite Barriers
Research suggests mifepristone, a drug used in medical abortions, may prevent breast cancer by blocking progesterone's effects on breast cells; however, ethical concerns, high costs, and limited large-scale trials hinder its wider application.
Progress
40% Bias Score
Russia's Mifepristone Restrictions Cause Nationwide Contraceptive Shortage
Russia's September 2024 reclassification of mifepristone as a controlled substance has led to a nationwide shortage of emergency contraceptives and medical abortion drugs, impacting women's reproductive healthcare access amid a demographic crisis and record-low birth rates.
Russia's Mifepristone Restrictions Cause Nationwide Contraceptive Shortage
Russia's September 2024 reclassification of mifepristone as a controlled substance has led to a nationwide shortage of emergency contraceptives and medical abortion drugs, impacting women's reproductive healthcare access amid a demographic crisis and record-low birth rates.
Progress
32% Bias Score
Trump Administration Moves to Dismiss Lawsuit Challenging Mifepristone Access
The Trump administration filed to dismiss a lawsuit from Idaho, Kansas, and Missouri seeking to restrict telehealth access to the abortion medication mifepristone, arguing the states lack legal standing and that their challenge to 2016 FDA actions is beyond the statute of limitations.
Trump Administration Moves to Dismiss Lawsuit Challenging Mifepristone Access
The Trump administration filed to dismiss a lawsuit from Idaho, Kansas, and Missouri seeking to restrict telehealth access to the abortion medication mifepristone, arguing the states lack legal standing and that their challenge to 2016 FDA actions is beyond the statute of limitations.
Progress
44% Bias Score
Trump Administration Defends Mifepristone Access in Legal Challenge
The Trump administration is defending FDA rules easing access to the abortion drug mifepristone against a lawsuit by three Republican states, arguing they lack standing and Texas is an improper venue; this maintains current access levels, affecting abortion availability nationwide.
Trump Administration Defends Mifepristone Access in Legal Challenge
The Trump administration is defending FDA rules easing access to the abortion drug mifepristone against a lawsuit by three Republican states, arguing they lack standing and Texas is an improper venue; this maintains current access levels, affecting abortion availability nationwide.
Progress
44% Bias Score
FDA Reviews Mifepristone Safety Amidst Political Pressure
The FDA is reviewing mifepristone's safety and efficacy following a letter from HHS Secretary Kennedy and FDA Commissioner Makary to Republican attorneys general, prompting concerns about potential restrictions on medication abortion access.
FDA Reviews Mifepristone Safety Amidst Political Pressure
The FDA is reviewing mifepristone's safety and efficacy following a letter from HHS Secretary Kennedy and FDA Commissioner Makary to Republican attorneys general, prompting concerns about potential restrictions on medication abortion access.
Progress
28% Bias Score
Lawsuit Challenges FDA Mifepristone Restrictions
In Honolulu, a lawsuit challenges FDA restrictions on the abortion drug mifepristone, arguing that they're unscientific and hinder access for those in low-income or rural areas; the judge will decide if these restrictions violate the law.
Lawsuit Challenges FDA Mifepristone Restrictions
In Honolulu, a lawsuit challenges FDA restrictions on the abortion drug mifepristone, arguing that they're unscientific and hinder access for those in low-income or rural areas; the judge will decide if these restrictions violate the law.
Progress
40% Bias Score
Republican AGs Demand Reinstatement of Mifepristone Safety Protocols
Twenty-two Republican attorneys general are demanding that the FDA reinstate safety protocols for the abortion drug mifepristone, citing studies showing serious adverse events are 22 times more frequent than stated on the label, and calling for stricter regulations or market removal if safeguards ar...
Republican AGs Demand Reinstatement of Mifepristone Safety Protocols
Twenty-two Republican attorneys general are demanding that the FDA reinstate safety protocols for the abortion drug mifepristone, citing studies showing serious adverse events are 22 times more frequent than stated on the label, and calling for stricter regulations or market removal if safeguards ar...
Progress
64% Bias Score
US Abortion Numbers Rise Despite State Bans
In 2024, a record 1.14 million abortions were performed in the US, despite bans in numerous states; this increase is largely due to telehealth abortions facilitated by "shield laws", while reported in-person abortions in states with total bans averaged only 30 per month.
US Abortion Numbers Rise Despite State Bans
In 2024, a record 1.14 million abortions were performed in the US, despite bans in numerous states; this increase is largely due to telehealth abortions facilitated by "shield laws", while reported in-person abortions in states with total bans averaged only 30 per month.
Progress
48% Bias Score
Trump Administration Defends Mifepristone Access Amidst Legal Challenge
The Trump administration is defending FDA regulations easing access to the abortion drug mifepristone against a lawsuit by three Republican-led states, arguing the states lack standing to sue in Texas federal court, while the states claim their Medicaid programs might have to pay for complications.
Trump Administration Defends Mifepristone Access Amidst Legal Challenge
The Trump administration is defending FDA regulations easing access to the abortion drug mifepristone against a lawsuit by three Republican-led states, arguing the states lack standing to sue in Texas federal court, while the states claim their Medicaid programs might have to pay for complications.
Progress
32% Bias Score
Trump FDA Dismisses Lawsuit Challenging Abortion Drug Mifepristone
The Trump administration's FDA moved to dismiss a lawsuit from conservative states aiming to limit access to the abortion drug mifepristone, echoing the Biden administration's position; medication abortions now comprise 63% of all abortions in the U.S.
Trump FDA Dismisses Lawsuit Challenging Abortion Drug Mifepristone
The Trump administration's FDA moved to dismiss a lawsuit from conservative states aiming to limit access to the abortion drug mifepristone, echoing the Biden administration's position; medication abortions now comprise 63% of all abortions in the U.S.
Progress
40% Bias Score
Showing 1 to 12 of 18 results